Table 2.
Analytical Sensitivity Analysis of MERS-CoV ORF1a and upE RT-iiPCR Assays Using Virus-Spiked Sputum Samples
| Sample no. | Virus amount (PFU/mL) |
ORF1a |
upE |
||
|---|---|---|---|---|---|
| RT-iiPCR | RT-qPCR (CT) | RT-iiPCR | RT-qPCR (CT) | ||
| SP1 | 3.7 × 101 | + | + (28.60) | + | + (28.28) |
| 3.7 × 100 | + | + (32.31) | + | + (31.92) | |
| 3.7 × 10−1 | + | + (35.58) | + | + (35.31) | |
| No virus | − | − | − | − | |
| SP2 | 3.7 × 101 | + | + (32.34) | + | + (31.35) |
| 3.7 × 100 | + | + (36.60) | + | + (35.30) | |
| 3.7 × 10−1 | + | − (38.93) | + | + (37.84) | |
| No virus | − | − | − | − | |
| SP7 | 3.7 × 101 | + | + (31.18) | + | + (30.85) |
| 3.7 × 100 | + | + (34.87) | + | + (34.75) | |
| 3.7 × 10−1 | + | + (36.92) | + | + (36.49) | |
| No virus | − | − | − | − | |
| SP8 | 3.7 × 101 | + | + (29.01) | + | + (28.65) |
| 3.7 × 100 | + | + (32.48) | + | + (32.14) | |
| 3.7 × 10−1 | + | + (36.34) | + | + (35.60) | |
| No virus | − | − | − | − | |
| SP9 | 3.7 × 101 | + | + (29.54) | + | + (29.12) |
| 3.7 × 100 | + | + (33.44) | + | + (32.78) | |
| 3.7 × 10−1 | + | + (34.61) | + | + (34.18) | |
| No virus | − | − | − | − | |
| SP10 | 3.7 × 101 | + | + (31.48) | + | + (30.94) |
| 3.7 × 100 | + | + (32.80) | + | + (32.33) | |
| 3.7 × 10−1 | + | + (36.35) | + | + (35.77) | |
| No virus | − | − | − | − | |
| SP11 | 3.7 × 101 | + | + (28.35) | + | + (28.39) |
| 3.7 × 100 | + | + (31.04) | + | + (30.80) | |
| 3.7 × 10−1 | + | + (32.87) | + | + (32.30) | |
| No virus | − | − | − | − | |
| SP13 | 3.7 × 101 | + | + (28.04) | + | + (28.23) |
| 3.7 × 100 | + | + (31.50) | + | + (31.96) | |
| 3.7 × 10−1 | + | + (32.62) | + | + (33.33) | |
| No virus | − | − | − | − | |
| SP14 | 3.7 × 101 | + | + (28.19) | + | + (28.50) |
| 3.7 × 100 | + | + (30.93) | + | + (30.86) | |
| 3.7 × 10−1 | + | + (32.30) | + | + (32.94) | |
| No virus | − | − | − | − | |
+, positive; −, negative; MERS-CoV, Middle East respiratory syndrome–coronavirus; PFU, plaque forming units; RT-iiPCR, reverse transcription-insulated isothermal PCR.